A Phase I Study With Expansion Cohort of Concurrent GDC-0084 With Radiation Therapy for Patients With Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Paxalisib (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 17 Apr 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
- 02 Oct 2024 According to a Kazia Therapeutics media release, Additional data, including circulating tumor DNA (ctDNA) from this study will be presented at an upcoming 2024 scientific congress